Experimental Drug Shows Promise in Lowering Cholesterol, Heart Attack Risk

March 15, 2015 4:00 PM

1 0

SUNDAY, March 15, 2015 (HealthDay News) -- Adding an experimental new biologic drug to conventional cholesterol-lowering drugs may result in better cholesterol control and reduced risks of heart attack and stroke, according to a new study.

Compared to patients on conventional therapy alone, those who also got the experimental drug evolocumab were half as likely to die, suffer a heart attack or a stroke or be in the hospital to have a procedure to open blocked arteries during the one-year follow-up, said lead researcher Dr. Marc Sabati...

Also read: Synergy Pharma's irritable bowel drug succeeds in key study

Read more

To category page

Loading...